SAT0254 Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs: results from select-next
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1202
Abstract: Background: Upadacitinib (UPA), a selective JAK-1 inhibitor, has demonstrated efficacy in active RA among patients with an inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD-IR).1 To understand treatment effectiveness from the patients’ perspective we… read more here.
Keywords: employee abbvie; abbvie; shareholder abbvie; employee ... See more keywords
SAT0255 Patient reported outcomes of upadacitinib: results from biologic inadequate responders (SELECT BEYOND PHASE III TRIAL)
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1254
Abstract: Background Patient reported outcomes (PROs) were studied in patients with active rheumatoid arthritis (RA) who had an inadequate response to biologic disease modifying anti-rheumatic drugs (bDMARD-IR) in a trial of upadacitinib (UPA), a selective JAK-1… read more here.
Keywords: employee abbvie; abbvie; shareholder abbvie; employee ... See more keywords
SAT0575 Safety and efficacy of lutikizumab (ABT-981), an anti–interleukin-1 alpha/beta dual variable domain (DVD) immunoglobulin, in subjects with knee osteoarthritis: results from the randomised, double-blind, placebo-controlled, parallel-group phase 2 trial
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2727
Abstract: Background Animal studies suggested that inhibiting IL-1α/β with lutikizumab (formerly, ABT-981) may reduce pain and slow structural progression in OA. Objectives This study (NCT02087904; ILLUSTRATE-K) assessed the safety and efficacy of lutikizumab in subjects with… read more here.
Keywords: employee; consultant abbvie; abbvie; shareholder abbvie ... See more keywords
SAT0576 Biomarkers predictive of pain improvement in knee osteoarthritis subjects treated with the anti-il-1 alpha/beta dual variable domain immunoglobulin lutikizumab (ABT-981)
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2730
Abstract: Background Development of disease-modifying drugs for OA has been challenging, partly due to lack of predictive biomarkers. Objectives Our primary objective was to identify baseline (BL) biomarkers predicting greater treatment effects on WOMAC pain among… read more here.
Keywords: shareholder abbvie; abbvie; employee; treatment ... See more keywords
POS0365 ANTI-TNF GLUCOCORTICOID RECEPTOR MODULATOR ANTIBODY DRUG CONJUGATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.2213
Abstract: Glucocorticoids (GC) are potent drugs used for treating many inflammatory diseases. While GCs are effective in many immune diseases, dose and duration of administration is limited due to significant side effects. Resting immune cells have… read more here.
Keywords: grant research; support abbvie; abbvie; research support ... See more keywords